The main market opportunities lie in PSMA-targeted therapies and radiodiagnostics, which are proving commercially successful for PET imaging and treatment of prostate cancer. Growth potential exists ...

KLK2-targeted immunotherapies present a promising opportunity in prostate cancer treatment. Elevated KLK2 in tumors and its surface expression make it an accessible target. Success in preclinical ...

A recent post hoc analysis assesses whether PSA changes can predict survival outcomes in patients with metastatic or very high risk nonmetastatic prostate cancer.

Study reveals geographic differences in the use of innovative technological approaches to diagnose and treat prostate cancer. The study looked at the effect of regional hospital competition and ...

One in eight men will develop prostate cancer in their lifetime. Surgery to treat the disease can lead to unwelcome side effects. A minimally invasive alternative that avoids surgery is now available ...

Read more in the PNW Health series. Prostate cancer is the second-most common cancer among men in the U.S., affecting 13 out of every 100 American men over the course of their lifetime. About two to ...